|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Acute Myelogenous Leukemia (AML)
Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The word "acute" in acute myelogenous leukemia denotes the disease's rapid progression and the fact that it affects immature blood cells, rather than mature ones. It's called myelogenous (MI-uh-loj-uh-nus) leukemia because it affects a group of white blood cells called the myeloid cells, which normally develop into the various types of mature blood cells, such as red blood cells, white blood cells and platelets.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Pediatric Leukemia - A2114
Phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of a twice daily investigational drug" and to evaluate the preliminary clinical and pharmacodynamic response when administered to pediatric patients ages 3 months to less than 18 years of age with one of the following relapsed or refractory leukemia's: 1. MLL (mixed-lineage-leukemia)-rearranged ALL (acute lymphocytic leukemia) patients 2. FLT3 (FMS-like tyrosine kinase receptor-3) mutated AML (acute myeloid leukemia) patients An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). This investigational drug may not become commercially available. Trial phase: phase 1/2 Participation Duration: Participants will be required to visit the study center 7 times during the first one month. If treatment continues, the participant will be asked to come to the office 3 times per month. Protocol Number: CPKC412A2114 |